All In MedTech

FDA Clearance Tracker · P240020

TOUCH® CMC 1 Prosthesis

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Jul 10, 2025 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

Jul 10, 2025

Approved

Time to decision

398 days

Received Jun 7, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P240020
Device name
TOUCH® CMC 1 Prosthesis
Applicant location
1228 Plan-Les-Ouates
Received
Jun 7, 2024
Decided
Jul 10, 2025
Decision
Approved
Supplements
6 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code SFA

FDA's approval statement

As written in FDA's record.

TOUCH® CMC 1 Prosthesis is indicated for 1st carpometacarpal (CMC) primary total joint replacement (arthroplasty) in patients with symptomatic Eaton-Littler stage II or III osteoarthritis (OA).

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code SFA (Prosthesis, finger, semi-constrained, metal/polymer).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Keri Medical SA

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.